Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptibleEscherichia colibloodstream infection

Overview of attention for article published in Annals of Clinical Microbiology and Antimicrobials, November 2020

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 26 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 3,231 followers.

Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection https://t.co/Om13FMaIZt

02 Dec 2020

Reply Repost Favourite

https://t.co/FjFQdtwycu Ceft-avib could be used to substitute 36.2 DOT/100 patient-days (54%) for inpatient definitive therapy, ceft-tazo for 34.7 DOT/100 patient-days (52%), cefiderocol for 27.1 DOT/100 (40%), fosfomycin for 23.3 DOT/100 (35%), plazomici

01 Dec 2020

Reply Repost Favourite

Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection https://t.co/2IQgcmxNkq

01 Dec 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.